Salvage therapy with JAK inhibitors in refractory Takayasu arteritis: a multicentre experience

RMD Open 2026 Open access

Read full text
Authors: Arsène Mekinian, Sarah Rubia Ferreira de Meneses, Lucie Biard, Lorenzo DAGNA, Pavel Novikov, Carlo Salvarani, Olivier Espitia, José Hernández‐Rodríguez, Karim Sacre, Bertrand Lioger, Virginie Dufrost, Alexandra Audemard-Verger
+10 more Alessandro Tomelleri, Masataka Kuwana, Vahan Mukuchyan, Azeddine Dellal, Francesco Muratore, Corrado Campochiaro, Sergey V. Moiseev, Patrice Cacoub, Olivier Fain, David Saadoun
DOI: 10.1136/rmdopen-2025-006501
Cited by: 1
References: 8

Abstract

Takayasu arteritis (TAK) remains a therapeutic challenge, and some patients develop refractory disease despite conventional immunosuppression and established biologics.1 2 We report here the data from the BIOTAK registry of multicentre experience with Janus kinase (JAK) inhibitors in 20 patients with refractory TAK, demonstrating promising efficacy and acceptable safety profiles.

Fields of Study & Subjects

Vasculitis and related conditions Renal Diseases and Glomerulopathies Peripheral Artery Disease Management

Publication details

Journal / source
RMD Open
Publisher
BMJ
Volume
12
Issue
1
Pages
e006501–e006501
Publication date
1 January 2026
Language
EN